Home / Healthcare / Pfizer’s COVID Vaccine Proves 94% Effective, in Global Study

Pfizer’s COVID Vaccine Proves 94% Effective, in Global Study

Spread the love

Ben Rees, a researcher of Harvard, told that” It is the first large-scale PIR review evidence to examine the effectiveness of the vaccine in the real-time world.”

A key player of pharmaceuticals, Pfizer’s vaccine is capable to control the COVID 94%, according to published a research report last Wednesday. Around 1,200,000 people from Israel were included in the study, in which Pfizer has seen a positive result. All of these have confirmed the vaccine provided by Pfizer is an effective vaccine to prevent infection.

It is very good news that Ghana is the first country who received vaccine shots first in the world.  The scheme has now paved the way for the poor countries to get the vaccine along with the rich countries of the world. According to a report published by the New England Journal of Medicine, the vaccine is very effective to prevent the spread of COVID infection.

One shot of Pfizer Covid vaccine is effective to prevent COVID: Study

“This is the first large-scale PIR review evidence to examine the effectiveness of the vaccine in real-world conditions”, Ben Rees told the news agency AFP (A researcher of Harvard Medical School). This involves around 600,000 people who received the COVID vaccine and those who did not take the vaccine analyzed according to age, gender, geography, and other characteristics.

Pfizer claims this COVID vaccine can be stored in common refrigerator

The study revealed that during the phase III trial, the vaccine is effective 94% of the second dose of the COVID vaccine. As per the latest report, around 217 million people have been vaccinated around the world.

About Siya

Siya
Siya has a master’s degree in Marketing and editor with passion. He holds 7 years’ experience in this field. She holds a keen interest in the know-how of what is brewing in healthcare and science.

Check Also

FDA greenlights Pfizer's inaugural gene therapy for rare inherited bleeding disorder

FDA greenlights Pfizer’s inaugural gene therapy for rare inherited bleeding disorder

Spread the love On Friday, the Food and Drug Administration (FDA) revealed its approval of ...